An antisense technology for silencing genes that contribute to hampered insulin production may help treat Type 2 diabetes.
United Therapeutics signed on to a collaboration with Israel-based CollPlant for the development of 3D-printed lung transplants.
The appointment puts Horgan in charge of a pipeline of drugs designed to treat disease through the alteration of the microbiome.
Bayer and Loxo Oncology have published the latest updated data for larotrectinib at ESMO.
The highest dose of the anti-GM-CSF antibody failed to beat the placebo on a disease activity score, but GSK plans to run more trials nonetheless.
LabCorp has tapped artificial intelligence-based image analysis company Definiens for a precision drug development collaboration in oncology.
Viseon received a 510(k) clearance from the FDA for its Voyant System for minimally invasive spine surgeries, including HD imaging and illumination.
Updated data show an objective response rate of 13% across 62 patients; treatment-naïve patients fared better than relapsed or refractory patients.
New data has shown positive results from a phase 3 looking at Novartis’ investigational oncology drug in combo with an old AZ breast cancer drug.
The multiyear contract will employ Congenica’s Sapientia genome interpretation software platform.